Warning letter
Biological Research Solutions Inc.: warning letter of Jan 16, 2001
FDA warning letter UCM069225 · Detroit District Office
Key facts
| Reference number | UCM069225 |
|---|---|
| Company | Biological Research Solutions Inc. |
| Subject | Good Manufacturing Practices for Finished Pharmaceuticals/Adulterated |
| Issue date | Jan 16, 2001 |
| Posted date | Jan 16, 2001 |
| Issuing office | Detroit District Office |
| Product type | Drugs |
| CFR sections cited | 211.22 |
| Country | 3 |
| Inspection city | Rochester Hills |
| Inspection ZIP | 48306-4375 |
| Inspection start date | Sep 13, 2000 |
| Letter on fda.gov | web.archive.org |
At a glance
- 1–9 CFR sections cited
- OAI Linked inspection classification
- Yes Form FDA 483 issued
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About FDA warning letters
FDA warning letters notify a firm of significant regulatory violations found during an inspection or review and request prompt corrective action.
Source: U.S. Food and Drug Administration (FDA), Warning Letters · Source date: